In HER2-Negative Metastatic Breast Cancer, Adding CDK4/6 Inhibitor to Endocrine Therapy Helps Survival

 Endocrine therapy plus cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improved overall survival, progression-free survival, and objective response rate for patients with hormone receptor–positive, HER2-negative metastatic breast cancer, according to results of a meta-analysis published recently in JAMA Oncology. The finding supports continued use of endocrine therapy plus CDK4/6 inhibitor combinations in clinical trials. The investigators, led by first author Jinming Li, BD, a pr...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.